DirectHit
Medical test used for the treatment of breast cancer / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about DirectHit?
Summarize this article for a 10 year old
DirectHit is a pharmacodiagnostic test used to determine the tumor sensitivity or resistance to drug regimens recommended for the treatment of breast cancer by the National Comprehensive Cancer Network.[1][2][3] It is a noninvasive test performed on small amounts of tissue removed during the original surgery lumpectomy, mastectomy, or core biopsy. DirectHit was developed by CCC Diagnostics Inc., a biotechnology company established by former researchers from Johns Hopkins University. DirectHit was launched on 14 January 2010.[4] Currently, it is the only available test for predicting treatment outcomes for anticancer chemotherapy drugs for breast cancer.[5]
DirectHit | |
---|---|
Purpose | determines tumor sensitivity |